Clinical Trials Browser

Phase 2 × Hemangiopericytoma × pembrolizumab × Clear all

NCT03016091 2025-02-18

A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma

Phase 2 Terminated

18 enrolled 9 charts

Hemangiopericytoma, Meningioma